

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jun 2026

### **Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years**

#### **Protocol summary**

##### **Study aim**

Evaluation of efficacy, safety and immunogenicity of recombinant protein vaccine in the prevention of symptomatic infection, severe disease and death due to SARS - CoV-2, in the population aged 18-80 years

##### **Design**

In a double blind randomized trial, 24,000 adults, aged between 18 and 80 years old (in 8 cities) will assign to the vaccine and placebo groups (4:1 ratio). The intervention in 6 cities, will be performed with two doses of vaccine and in 2 cities with three doses of vaccine.

##### **Settings and conduct**

This study will be conducted in 8 centers from 7 provinces. During the study, efficacy, safety and immunogenicity of two doses of Soberana 02 vaccine and two doses of Soberana 02 with one dose of Soberana plus will evaluate in comparison with the control group. Researchers and volunteers are not aware of the product prescription for each individuals.

##### **Participants/Inclusion and exclusion criteria**

Inclusion informed consent, 18-80 years, male and female, Iranian citizens, healthy adults/adults with controlled underlying diseases, able to comply with schedule, subjects from 8 cities Exclusion Fever or infectious disease (recently), mental diseases, severe allergies, complicated diseases (asthma, hypertension, renal, liver and hart diseases), application of tetanus vaccines (recently), vaccination against SARS-CoV-2, use of immunomodulators, tattoos on arms, participation in COVID-19 vaccine trials, Blood transfusion and its products (recently), Coagulation problems, heavy smoker-First priority groups for vaccination

##### **Intervention groups**

Cohort 1: 25 µg of RBD-TT, IM, 0 - 28 Cohort 2: 25 µg of

RBD-TT, IM, 0 - 28 + a booster dose (Soberana Plus), 56 Placebo groups: Aluminum hydroxide, IM, 0.5 mL, 0 - 28 (& 56 in Cohort 2)

##### **Main outcome variables**

PCR-confirmed of Covid-19 between day 14 and 75 and day 14 and 90 after the last dose, respectively in the 2-dose and the 2-dose+booster regimens.

#### **General information**

##### **Reason for update**

Due to the small number of volunteers who were above 65 years (as they have had access to COVID-19 vaccine from the national health system), the 10% limit for recruitment of the above 65 years age group was removed from the protocol upon approval of the DSMB. As per the request of the DSMB committee, new sample size is estimated for the cellular immunity assessment. Accordingly, the following fields in the IRCT were updated: - Secondary outcome variable section> description of the third outcome variable> the sample size for cellular immunity assessment is changed to 130 people. - Abstract section > Study Design section: e 10% limit for recruitment of the above 65 years age group is removed.

##### **Acronym**

##### **IRCT registration information**

IRCT registration number: **IRCT20210303050558N1**

Registration date: **2021-04-24, 1400/02/04**

Registration timing: **prospective**

Last update: **2021-11-07, 1400/08/16**

Update count: **2**

##### **Registration date**

2021-04-24, 1400/02/04

## Registrant information

### Name

Ehsan Mostafavi

### Name of organization / entity

### Country

Iran (Islamic Republic of)

### Phone

+98 21 6411 2121

### Email address

mostafaviehsan@gmail.com

## Recruitment status

### Recruitment complete

## Funding source

## Expected recruitment start date

2021-04-25, 1400/02/05

## Expected recruitment end date

2021-05-20, 1400/02/30

## Actual recruitment start date

empty

## Actual recruitment end date

empty

## Trial completion date

empty

## Scientific title

Efficacy, safety, and immunogenicity of Soberana recombinant vaccine (product of Finlay Institute) based on RBD protein subunit of Sars-Cov-2 in a 2-dose regimen with and without a booster dose: a double-blind, randomized, placebo-controlled phase III clinical trial in the Iranian population of 18-80 years

## Public title

Efficacy, safety and immunogenicity of Soberana 02 vaccine (product of Finlay Institute): a double-blind, randomized, placebo-controlled phase III clinical trial

## Purpose

Prevention

## Inclusion/Exclusion criteria

### Inclusion criteria:

Giving written informed consent Ability to comply with the vaccination plan, scheduled visits and lab tests Having general health and controlled underlying diseases Iranian citizenship Residing in the studied cities (Isfahan, Babol, Bandar Abbas, Zanjan, Kerman, Hamedan, Yazd and Sari) Both Genders Aged 18 to 80 years

### Exclusion criteria:

Pregnant or lactating women or those who plan to become pregnant up to 3 months after the last dose of the vaccine Application of vaccines containing tetanus toxoid in the last 3 months History of blood /blood products transfusions such as immunoglobulin in the last three months Type 2 diabetes ( HbA1c higher than 7.5) Chronic liver disease (liver enzymes more than 5 times normal: ALT $\geq$ 150, AST $\geq$ 100) Subjects previously vaccinated against SARS-CoV-2. History of psychiatric disorders Uncontrolled asthma (having an asthma attack in the last three months). History of severe allergic reaction (anaphylaxis) to the vaccine throughout life History of smoking more than 20 cigarettes a day for more than twenty years Coagulation problems that

contraindicate IM injection Previous vaccination with any coronavirus vaccine or participation in other COVID-19 vaccine trials Treatment with immunomodulators in the last 30 days Uncontrolled hypertension (cytological pressure more than 140, diastolic pressure more than 90 mm Hg) Fever or acute illness for 7 days before the injection or on the day of the injection Chronic kidney disease (GFR less than 30) All individuals who are in phase one priority of vaccination based on the National COVID-19 Vaccination Program (health workers can participate if they give consent) Subjects with tattoos in the deltoid region on both arms

## Age

From **18 years** old to **80 years** old

## Gender

Both

## Phase

3

## Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser
- Data and Safety Monitoring Board

## Sample size

Target sample size: **24000**

## Randomization (investigator's opinion)

Randomized

## Randomization description

The random chain will be defined in the system before the start of the study and the list of randomized treatment groups and the corresponding codes will be delivered to the Food and Drug Administration. Random codes and the type of intervention will be assigned to the candidates based on this list, the details of which are given in the following sections. The random chain in this study will be based on the stratified block randomization method. Stratified randomization will be based on studied cities and the randomization unit is individual participants. Random blocks are a common method for constructing and allocating interventions in clinical trials in which the sample size is divided into a number of blocks of a certain size and in each block the ratio of intervention and control groups in the study is observed. Using this method, it is possible to ensure that the ratio of the intervention group to the control is observed at any time during the study. In the present study, the sample size of 24,000 people in 8 study centres (3000 people in each centre) has been determined. Each centre also has 500 codes in excess of the study size to meet the extraordinary needs of the study (for example, the decision to increase the sample size in one of the centres). The size of the blocks is 25. Therefore, for each centre, 3500 codes in 140 random blocks will be considered, in each of which there are 20 intervention codes and 5 control codes. Each intervention or control code has a unique block ID in the form of a UUID, a 1-digit code for the study centre, a block code from 1 to 140 for labeling vial-holding blocks, and a volunteer

code. The volunteer code consists of 5 digits, the first digit of which is the code of the study centre and 4 digits after 1 to 3000 and is therefore unique in the study. Random chain construction is done through a program written specifically for this study. Random chain construction will be performed through a randomization program using the Python 3.8.2 programming language, which was written specifically for this study. In this program, first the total sample size, number of centers, block size, number and ratio of interventions as well as the intervention label are defined. The program then calculates the required number of blocks for each center based on its sample size and block size and creates random chains for each block. In summary, in this method, first a list of intervention and control codes in a block will be made by observing the ratio of the groups. The ordering of the indices is done using a random process in which one of the indices is selected at each stage using a uniform distribution, added in the final order and removed from the unselected indices. This process is repeated for each block.

#### **Blinding (investigator's opinion)**

Double blinded

#### **Blinding description**

The unique codes of the volunteers are delivered to the preparation group and a label with the volunteer code is inserted on each vial. None of the people working in the preparation department will be in contact with those are involved in the site. Therefore, at the time of delivery of the vial block to the centres, the study colleagues will not be able to distinguish between the drug vial and the placebo. The suspensions in the vaccine and placebo vials are milky white and are similar in color and clarity. Moreover, vaccine and placebo vials are offered in similar appearance, they are inseparable, and packaging and are placed in boxes of 25. Each box will contain the block number and serial numbers of the vaccine/placebo inside. According to this process, participants, vaccinators, researchers, and outcome assessors will be blind. Vaccinators check the unique code information assigned to the candidate with the code on the vaccine/placebo vial before injection. During the study, all consumed vials will be archived and maintained.

#### **Placebo**

Used

#### **Assignment**

Parallel

#### **Other design features**

### **Secondary Ids**

empty

### **Ethics committees**

#### **1**

##### **Ethics committee**

###### **Name of ethics committee**

National Committee for Ethics in Biomedical Research

###### **Street address**

Sima-Ye-Iran St, Shahrak Gharb, Ministry o Health,

Treatment and Medical Education

###### **City**

Tehran

###### **Province**

Tehran

###### **Postal code**

1467664961

###### **Approval date**

2021-04-17, 1400/01/28

###### **Ethics committee reference number**

IR.NREC.1400.001

### **Health conditions studied**

#### **1**

##### **Description of health condition studied**

Coronavirus Disease (COVID-19)

##### **ICD-10 code**

U11

##### **ICD-10 code description**

Need for immunization against COVID-19

### **Primary outcomes**

#### **1**

##### **Description**

The effectiveness of the vaccine in preventing symptomatic Covid-19 infection

##### **Timepoint**

2-dose regimen: Day 14 and 75 days after dose-2 injection; 2-dose + booster regimen: Day 14 after dose-2 injection and 90 days after booster

##### **Method of measurement**

Real Time PCR test results for COVID-19

### **Secondary outcomes**

#### **1**

##### **Description**

Humoral safety will be studied on a subset of the population of Babol, Sari (under 2-dose regimen) and Zanjan (under 2-dose + booster regimen).

##### **Timepoint**

The Humoral test will be done before and 1 month after receiving the last dose. Also, in Babol and Sari, an additional assessment will be done on days 5 and 28 of a 30% sample of subjects (900 people in each city).

##### **Method of measurement**

EISA test

#### **2**

##### **Description**

The frequency of local and systemic events and mild, moderate , severe, critical adverse events and death will be recorded by the participants in the forms.

##### **Timepoint**

The occurrence of side effects and adverse events will be monitored from Zero day to 5 months after the injection

of the last dose.

#### **Method of measurement**

Active and inactive monitoring from Zero day to 5 months after the injection of the last dose with the registration of adverse events in CIFs

### **3**

#### **Description**

Evaluation of Cellular safety will be performed on 130 people in one of the cities of Babol or Sari (depending of logistic status).

#### **Timepoint**

Cell immunoassay will be performed at the same time as the humoral tests.

#### **Method of measurement**

Interferon Gamma Release Assay

### **4**

#### **Description**

The effectiveness of the vaccine in preventing severe form of Covid-19

#### **Timepoint**

2-dose regimen: Day 14 and 75 days after dose-2 injection; 2-dose + booster regimen: Day 14 after dose-2 injection and 90 days after booster

#### **Method of measurement**

Based on the patient's clinical condition, like respiratory symptoms such as dyspnea and tachypnea, SpO2 of lower than 90%, and lung involvement of more than 50%, or hospitalization.

### **5**

#### **Description**

The effectiveness of the vaccine in prevention of death from Covid-19

#### **Timepoint**

All cases of death due to COVID-19 will be detected: 2-dose regimen: Day 14 and 75 days after dose-2 injection; 2-dose + booster regimen: Day 14 after dose-2 injection and 90 days after the booster

#### **Method of measurement**

According to the diagnosis of the research physician and the DSMB team and based on the definition of the World Health Organization

### **6**

#### **Description**

SARS-CoV-2 virus neutralization assay

#### **Timepoint**

Based on serum samples on day 0 and up to 1 month after receiving the last dose of vaccine in 10% of antibody positive volunteers

#### **Method of measurement**

Viral neutralization tests (VNTs)

## **Intervention groups**

### **1**

#### **Description**

Intervention group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 80% of people (14,400 people) receive the intervention (vaccine) after random allocation. Intervention is included intramuscular injection of vaccine candidates with conjugation of 25 µg RBD to tetanus toxin in a 2-dose program (days 0 and 28). This vaccine is made by the Finlay Institute of Vaccines.

#### **Category**

Prevention

### **2**

#### **Description**

Control group in the first cohort: In 6 cities (Isfahan, Babol, Bandar Abbas, Sari, Kerman and Hamedan) 20% of people (3600 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0 and 28. This placebo is made by the Finlay Institute of Vaccines.

#### **Category**

Placebo

### **3**

#### **Description**

Intervention group in the second cohort: In two cities (Zanjan and Yazd) 80% of people (4800 people) receive the intervention (vaccine) after random allocation. The intervention includes: a 2-dose program + a booster dose (days 0, 28, 56). The booster dose of the candidate vaccine is Sobrana Plus (50 micrograms d-RBD +, IM 0.5 ml). This vaccine is made by the Finlay Institute of Vaccines.

#### **Category**

Prevention

### **4**

#### **Description**

Control group in the second cohort: In 2 cities (Zanjan and Yazd) 20% of people (1200 people) receive a placebo after random allocation. The intervention involves an intramuscular injection of a dose of aluminum hydroxide on days 0, 28 and 56. This placebo is made by the Finlay Institute of Vaccines.

#### **Category**

Placebo

## **Recruitment centers**

### **1**

#### **Recruitment center**

##### **Name of recruitment center**

Shahid Nilforuzadeh Hall, on the campus of Isfahan University of Medical Sciences

##### **Full name of responsible person**

Dr. Morteza Pourahmad

**Street address**

Hezar Jerib St., Isfahan University of Medical Sciences and Health Services

**City**

Isfahan

**Province**

Isfahan

**Postal code**

۷۳۴۶۱-۸۱۷۴۶

**Phone**

+98 31 3668 0048

**Email**

mortezapourahmad@yahoo.com

**2****Recruitment center****Name of recruitment center**

Sport Hall of Babol University of Medical Sciences and Health Services

**Full name of responsible person**

Dr. Mostafa Javanian

**Street address**

Ganj Afrooz St., Babol University of Medical Sciences, Babol, Mazandaran

**City**

Babol

**Province**

Mazandaran

**Postal code**

۴۷۷۴۵-۴۷۷۷۶

**Phone**

+98 11 3219 9592

**Email**

sfjalali42@yahoo.com

**3****Recruitment center****Name of recruitment center**

Behvarz Training Center

**Full name of responsible person**

Dr.Hossein Farshidi

**Street address**

Payambar Azam Town, Hormoz Boulevard, Green Tree Site Phase 2

**City**

Bandar Abass

**Province**

Hormozgan

**Postal code**

7919693116

**Phone**

+98 76 3371 0371

**Email**

Traznahan@yahoo.com

**4****Recruitment center****Name of recruitment center**

School of Nursing and Midwifery, Mazandaran University of Medical Sciences

**Full name of responsible person**

Dr. Roya Ghasemian

**Street address**

Imam Square, Joybar Three Ways, beginning of Valiasr Highway, Mazandaran University of Medical Sciences, Sari

**City**

Mazandaran

**Province**

Mazandaran

**Postal code**

4815733971

**Phone**

+98 11 3304 4000

**Email**

roya31gh@gmail.com

**5****Recruitment center****Name of recruitment center**

Corona Vaccine Clinical Trial Center, Zanzan University of Medical Sciences

**Full name of responsible person**

Dr. Samad Ghodrati

**Street address**

Amirkabir crossroads, next to Zanzan county health center

**City**

Zanzan

**Province**

Zanzan

**Postal code**

4513956184

**Phone**

+98 24 3315 6201

**Email**

ghodrati@zums.ac.ir

**6****Recruitment center****Name of recruitment center**

Health Technology Incubator of Kerman University of Medical Sciences

**Full name of responsible person**

Dr. Iman Ghasemzadeh

**Street address**

Kerman Health Technology, between Farhangian interchange & Amirkabir interchange, Jomhourli blvd

**City**

Kerman

**Province**

Kerman

**Postal code**

76188-66749

**Phone**

+98 34 3211 4534

**Email**

imanaten@gmail.com

## 7

### Recruitment center

**Name of recruitment center**

Shahid Soleimani Sports Hall, Hamadan University of  
Medical Sciences and Health Services

**Full name of responsible person**

Dr. Fariba Keramat

**Street address**

Palestine Square, Shahid Soleimani Sports Hall

**City**

Hamedan

**Province**

Hamadan

**Postal code**

6517838678

**Phone**

+98 81 3525 0182

**Email**

faribakeramat@yahoo.com

## 8

### Recruitment center

**Name of recruitment center**

Akbari Health Center

**Full name of responsible person**

Dr. Mohammadreza Mirjalili

**Street address**

Safaieh, Imam Hassan Square, Shahid Karimi Street,  
in front of Safaieh Hotel

**City**

Yazd

**Province**

Yazd

**Postal code**

8916978477

**Phone**

+98 35 3725 8474

**Email**

Dr.mirjalili@ssu.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

**Name of organization / entity**

Pasture Institute of Iran

**Full name of responsible person**

Dr Alireza Biglari

**Street address**

No. 69, 12 Farvardin St., Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1316943551

**Phone**

+98 21 6695 4321

**Email**

biglari63@hotmail.com

**Web page address**

<http://fa.pasteur.ac.ir/>

**Grant name**

Pasteur institute of Iran

**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Pasture Institute of Iran

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin****Type of organization providing the funding**

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Pasture Institute of Iran

**Full name of responsible person**

Dr. Ehsan Mostafavi

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Epidemiology

**Street address**

No. 69, 12 Farvardin St., Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1316943551

**Phone**

+98 21 6411 2121

**Email**

mostafaviehsan@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Hamid Emadi Kuchak

**Position**

Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Infectious diseases

**Street address**

Enghela street, Tehran University of Medical Sciences

**City**

Tehran

**Province**

Tehran

**Postal code**

1467664961

**Phone**

+98 21 8897 3372

**Email**

emadiham@tums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Pasture Institute of Iran

**Full name of responsible person**

Dr. Sana Eybpoosh

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Epidemiology

**Street address**

No. 69, 12 Farvardin St., Tehran

**City**

Tehran

**Province**

Tehran

**Postal code**

1316943551

**Phone**

+98 21 6411 2121

**Email**

mostafaviehsan@gmail.com

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available